Although PD-1/PD-L1 blockade can increase anti-tumor activity of donor T cells [44, 45], antibodies to PD-1/PD-L1 increase GvHD lethality and mortality in allo-HSCT recipient mice [16]. This evidence concerns the gene CD274 and neoplasm.